StockDocs
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
BCTX

BriaCell Therapeutics Corp.

BCTXZ Nasdaq Pharmaceutical Preparations EDGAR ↗
$0.09
+0.00 0.00%

Key statistics

from XBRL data in SEC filings
Market cap
$782K
Revenue (TTM)
Net income (TTM)
-$30.7M
EPS (TTM)
$2.29
P/E ratio
0.0
Dividend yield
Free cash flow
-$28.6M
Cash
$6.88M
Total assets
$27.1M
Gross margin
52-week range
$0.07 – $0.11

Recent SEC filings

40 most recent
Annual, quarterly & current reports
8-K Regulation FD disclosure Jun 26, 2026 10-Q Quarter ended 2026-04-30 Jun 9, 2026 8-K Entered a material agreement; Unregistered sale of equity; Other events Jun 3, 2026 8-K Regulation FD disclosure Mar 31, 2026 10-Q Quarter ended 2026-01-31 Mar 10, 2026 8-K Shareholder vote results Mar 9, 2026 8-K Other events Feb 20, 2026 8-K Entered a material agreement; Other events Jan 15, 2026 8-K Regulation FD disclosure Dec 29, 2025 10-Q Quarter ended 2025-10-31 Dec 11, 2025 8-K Regulation FD disclosure Dec 1, 2025 10-K Fiscal year ended 2025-07-31 Oct 16, 2025 8-K Other events Aug 26, 2025 8-K Entered a material agreement; Other events Jul 16, 2025 8-K Regulation FD disclosure Jun 18, 2025 10-Q Quarter ended 2025-04-30 Jun 16, 2025 8-K Entered a material agreement; Other events Apr 28, 2025 10-Q Quarter ended 2025-01-31 Mar 12, 2025 8-K Regulation FD disclosure Mar 12, 2025 8-K Other events Feb 13, 2025 8-K Shareholder vote results Feb 6, 2025 8-K Entered a material agreement; Unregistered sale of equity; Other events Feb 5, 2025 8-K Other events Jan 28, 2025 8-K Other events Jan 3, 2025 8-K Other events Jan 3, 2025 10-Q Quarter ended 2024-10-31 Dec 16, 2024 8-K Regulation FD disclosure Dec 16, 2024 8-K Entered a material agreement; Unregistered sale of equity; Other events Dec 13, 2024 8-K Director or officer change Nov 25, 2024 8-K Regulation FD disclosure Nov 1, 2024 10-K Fiscal year ended 2024-07-31 Oct 29, 2024 8-K Entered a material agreement; Other events Oct 2, 2024 8-K Other events Oct 1, 2024 8-K Entered a material agreement; Unregistered sale of equity; Other events Sep 12, 2024 8-K Other events Sep 11, 2024 8-K Delisting notice or listing-rule failure Aug 23, 2024 8-K Regulation FD disclosure Jul 18, 2024 8-K Delisting notice or listing-rule failure Jul 5, 2024 10-Q Quarter ended 2024-04-30 Jun 14, 2024 8-K Regulation FD disclosure Jun 14, 2024